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Keep on taking the medicine? 
How do you help someone who doesn’t see the point of taking their medication? 
Parastou Donyai considers strategies for understanding and tackling medication non-
adherence 
Imagine a patient who is 60 and recovering from breast cancer. She was treated in hospital 
with surgery, chemotherapy and radiotherapy six months ago. She was then sent home with 
letrozole tablets, a hormonal treatment, and told to take them once a day for the next five 
years. Since starting the letrozole tablets, she has been experiencing night sweats, hot flushes 
and headaches. She complains that the GP, although very nice, doesn’t want to discuss her 
medication with her as this is related to her cancer which ‘the hospital treated’. She tells you 
that she’s unlikely to continue with her medication for much longer, seeing that taking 
letrozole will mean spoiling the last ‘good five years’ of her life. How would you respond?  
Medication is the most common intervention in healthcare. Community pharmacies 
dispensed over a thousand million prescribed items in England in 2015; an average of 20 
items for every inhabitant. Scotland and Northern Ireland had a similar average with Wales 
pharmacies dispensing 26 items for each inhabitant. This is perhaps to be expected as 
prescribers use medication to prevent, treat or manage a range of conditions. Consider that 
there is a large proportion of elderly people in the UK and they are likely to have medical 
conditions needing treatment. Also, across the population people have different chronic 
conditions, such as diabetes, which are managed with medication. In addition, a number of 
guidelines encourage doctors to prescribe medicines to prevent illnesses; for example, lipid-
lowering medication to reduce the risk of stroke or heart attacks. In relation to the 60-year old 
patient described above, the National Institute for Health and Care Excellence (NICE) 
recommends prescribing aromatase inhibitors (a form of hormonal treatment) such as 
letrozole to delay the return of cancer and increase overall survival in women who receive 
treatment for early-stage breast cancer after the menopause. 
Medicines for conditions affecting the mind and the nervous system (e.g. mental health 
conditions) cost the most, followed by conditions affecting the endocrine (e.g. diabetes), 
respiratory (e.g. asthma), and cardiovascular (e.g. high blood pressure) systems. Items 
dispensed in England in 2015 had a Net Ingredient Cost of £9,266.6 million. Despite the 
expenditure, people commonly fail to take their dispensed medication as instructed. This 
article asks what progress has been made in understanding and tackling medication-taking 
behaviour since the subject was last covered by The Psychologist over a decade ago in 2005. 
Definition of adherence 
We are going to use the term medication adherence when referring to medication-taking 
behaviour—instead of medication compliance, which carries a negative inference of passive 
obedience (Sabaté, 2003). Medication adherence is about how the patient takes their 
medication compared with the instructions on their prescription. There are three stages to 
adherence. The first is the initiation stage which is whether the patient takes the first dose as 
prescribed. Next is the implementation stage which is ‘the extent to which a patient’s actual 
dosing corresponds to the prescribed dosing regimen, from initiation until the last dose is 
taken’. The final stage is the discontinuation stage which is whether the patient takes the last 
dose as prescribed (Vrijens, et al., 2012). Another key term is persistence, which is the length 
of time between the initiation stage and the discontinuation stage. A patient can be non-
adherent to their medication regimen if they fail to collect and take their medication on time, 
if at all (described as primary non-adherence), if they don’t follow the dosing regimen during 
the implementation stage (secondary non-adherence), and if they discontinue the course early 
(non-persistence). One other term for us to consider is concordance. It describes a medical 
consultation process whereby the prescriber and patient agree therapeutic decisions that 
incorporate both views, and the term also encompasses prescriber communication and patient 
support in medicine taking (Horne, et al., 2005). 
The extent of the problem  
The World Health Organisation estimated in 2003 that patients do not take between 30-50% 
of medicines prescribed for long-term conditions as intended, and this remains an often-used 
statistic to depict the extent of the medication non-adherence problem (Sabaté, 2003). 
Measuring the true prevalence of medication non-adherence in chronic conditions has been 
particularly difficult because no methodological gold standard exists to measure the range of 
non-adherent behaviours (Vermeire, Hearnshaw, Van Royen, & Denekens, 2002). 
Researchers have used subjective methods (e.g. by asking the patient to report their 
adherence), objective approaches (e.g. by using electronic monitoring devices to record doses 
accessed, or pharmacy databases to look at the frequency of dispensing), as well as direct 
methods (e.g. biochemically measuring the amount of drug in the patient’s body, or placing a 
microchip inside the medication form) to quantify adherence behaviour, but none is a perfect 
instrument (Dodds, Rebair-Brown, & Parsons, 2000). In addition, researchers have used 
different ways to quantify adherence, calculating for example, the proportion of prescribed 
drug taken, days with correct number of doses, doses taken on time, or the number of drug 
holidays, and so on (Vrijens, et al., 2012). This heterogeneity in measurement means it is 
difficult to accurately compare adherence between different conditions.  
 
However, we can draw on a useful US study which compared adherence and persistence 
across 6 chronic medication classes using one methodology. It found variable but uniformly 
suboptimal use with medication prescribed for diabetes (mean 12-month adherence rate 
72%), overactive bladder (35%), cholesterol (61%), cardiovascular disease (66%), 
osteoporosis (60%), and glaucoma (37%) (Yeaw, Benner, Walt, Sian, & Smith, 2009). Other 
chronic conditions where patients are known to be non-adherent include Human 
Immunodeficiency Virus (HIV), arthritis, gastrointestinal disorders, cancer, pulmonary 
disease, mental health disorders and epilepsy (DiMatteo, Giordani, Lepper, & Croghan, 2002; 
Sabaté, 2003). When people don’t adhere to their medication this can reduce the clinical 
benefit of the medication and in turn affect the patient’s quality of life. Medication non-
adherence affects health systems by increasing the burden of ill health, medicines waste, 
hospitalisation and emergency admission as well as death (Simpson, et al., 2006; DiMatteo, 
Giordani, Lepper, & Croghan, 2002). 
The Psychology 
Some consider medication non-adherence to be either unintentional (e.g. due to forgetfulness 
or carelessness) or intentional (e.g. not believing in the treatment) although this is an over-
simplification since people’s beliefs can also predict unintentional non-adherence (Gadkari & 
McHorney, 2012). One psychological model of medication adherence is the Necessity-
Concerns Framework, which concentrates on intentional non-adherence. At its heart is the 
idea that patients’ common-sense beliefs about prescribed medicines can be captured and 
categorised according to necessity beliefs, perceptions of personal need for treatment, and 
concerns about a range of potential adverse consequences—and that intentional adherence is 
associated with greater necessity beliefs versus concerns (Horne, R; Weinman, J, 1999). The 
associated Beliefs about Medicines Questionnaire quantifies necessity beliefs and concerns 
(Horne, R; Weinman, J; Hankins, M, 1999) with its originators encouraging healthcare 
professionals to use it within clinical consultations to elicit and respond to patient beliefs 
(Horne, et al., 2013). Other tools for screening non-adherence across chronic diseases also 
exist (Svarstad, Chewning, Sleath, & Claesson, 1999; Willey, et al., 2000; George, 
Mackinnon, Kong, & Stewart, 2006; Hahn, et al., 2008; McHorney, 2009). However, it is 
important to note that practitioners as a whole have not adopted any of these tools widely in 
practice and non-adherence remains a complex problem that is yet unresolved. 
A multitude of studies have examined the psychological causes of non-adherence across 
chronic health conditions and patient characteristics, emphasising different factors such as the 
severity of the disease and whether symptoms are present, patients’ perception of their 
condition and sense of vulnerability, their concerns about medication side-effects and long-
term consequences, their knowledge about a medicine’s mechanism of action, and their 
health literacy in general, the complexity of the regimen, patient forgetfulness, their fear of 
dependence, and so on (Sabaté, 2003; Vermeire, Hearnshaw, Van Royen, & Denekens, 2002; 
Pound, et al., 2005; Kardas, Lewek, & Matyja, 2013). This reflects the current understanding 
that the reasons for non-adherence are multifaceted and not easy to categorise.  
The World Health Organisation (WHO) report on adherence described five interacting 
dimensions of non-adherence to be healthcare system/team factors, patient-related factors, 
therapy-related factors, condition-related factors, and social and economic factors (Sabaté, 
2003). The WHO report defined patient-related factors of adherence to be the resources, 
knowledge, attitudes, beliefs, perceptions and expectations of the patient (Sabaté, 2003). It 
identified the major patient-related barriers to adherence to be lack of information and skills 
as they relate to self-management, difficulty with motivation and self-efficacy, and lack of 
support for behavioural changes (Sabaté, 2003). The report advocated the development of 
self-management interventions aimed at improving motivation and adherence noting that 
‘patients need to be informed, motivated and skilled in the use of cognitive and behavioural 
self-regulation strategies if they are to cope effectively with the treatment-related demands 
imposed by their illness’ (Sabaté, 2003). 
The Evidence 
A 2014 Cochrane review examined 182 randomised controlled trials (RCTs) of interventions 
to improve adherence with prescribed medications, measuring both medication adherence and 
clinical outcomes (Nieuwlaat, et al., 2014). It found that researchers most frequently targeted 
conditions including HIV/AIDS, psychiatric disorders, chronic obstructive pulmonary 
disease, cardiovascular disease or cardiovascular risk, hypertension, and diabetes. The 
Cochrane reviewers identified seventeen studies as having a low risk of bias with only five 
reporting improvements in both adherence and clinical outcomes; three improved only 
adherence outcomes, one improved only clinical outcomes, and the remainder did not 
improve adherence or clinical outcomes. They found no study that led to large improvements 
and also found no obvious common study characteristics. The authors noted the most robust 
designs generally involved complex interventions with multiple components, where 
healthcare professionals (e.g. pharmacists) gave ongoing tailored support, often delivering 
intense education, counselling (including motivational interviewing or cognitive behavioural 
therapy by professionals) or daily treatment support (or both), and sometimes there was 
additional support from family or peers (Nieuwlaat, et al., 2014). However, the reviewers 
could not make a judgement about which intervention type was most effective because of the 
diversity and complexity of the studies (e.g. the variety of settings, participants, intervention 
types, medications, adherence measures, and clinical outcome).  
The European ABC project also reviewed RCTs but included only studies where researchers 
had assessed adherence by electronic medication-event monitoring—this consists of an 
automatic, electronically-compiled drug dosing history for each patient (Demonceau, et al., 
2013). The ABC’s systematic reviewers examined the determinants of adherence using a 
multiple regression model as well as a meta-analysis. Both the multiple regression model and 
the meta-analysis found statistically significant increases in adherence when the intervention 
included feedback to patients using electronic monitoring, EM-feedback, or involved a 
cognitive-educational component Cogn-Educ. To elaborate, EM-feedback involved a focused 
discussion based on giving feedback to the patient of his/her recent dosing history data, as a 
guided example of behavioural-counselling. Cogn-Educ interventions presented information 
individually or in a group setting, verbally, in written form, and/or audiovisually, in order to 
educate and motivate patients—the rationale is that patients who understand their condition 
and its treatment will be more informed, more empowered and more likely to adhere. The 
ABC’s systematic reviewers also examined and reported on intervention components  
(Demonceau, et al., 2013). For example, studies using rewards although demonstrated median 
improvement, had a small sample size and thus did not demonstrate statistical significance. 
The other techniques that also did not demonstrate clinical significance included treatment 
simplification, behavioural-counselling interventions, social-psycho-affective interventions, 
technical reminder systems, and providing technical equipment for disease monitoring.  
The research in this area is complex and conflicting. For example, an earlier systematic 
review of adherence in chronic conditions found the most effective interventions to be those 
that simplify dosing demands as well as those involving monitoring and feedback, and 
multisession informational trials (Kripalani, Yao, & Haynes, 2007). A meta-review of over 
1,300 original articles also concluded that effective adherence interventions include technical 
solutions such as simplifications of dosage and packaging (van Dulmen, et al., 2007). Perhaps 
the common thread to all reviews of medication-adherence interventions is that there is no 
consistent quantifiable evidence of effectiveness associated with any particular intervention 
type. We might form the view that there is a need for further research to provide more robust 
evidence linking behaviour-change interventions with improved adherence, e.g. leading either 
to a large improvement in adherence or in clinical outcomes. But another view we might form 
is that the factors of non-adherence are so complex, that no single intervention or package of 
interventions could ever be effective across patients, conditions and settings. It would follow 
that instead of pursuing a truth-seeking, reductionist search for effective interventions we 
should focus on providing a concordant, client-centred approach to medicines adherence by 
listening to our patients and addressing their concerns.  
The advice 
In keeping with a client-centred approach, the current National Institute for Health and Care 
Excellence (NICE) guideline on medicines adherence makes recommendations for healthcare 
professionals (who prescribe, dispense, or review medicines or who have a role in making 
decisions about medicines with patients), under the following broad headings: 
 Patient involvement in decisions about medicines (communication, increased patient 
involvement, understanding the patient’s knowledge, beliefs and concern about 
medicines, providing information) 
 Supporting adherence (assessing adherence, interventions to increase adherence) 
 Reviewing medicines and 
 Communication between healthcare professionals (NICE, 2009). 
Thus, according to NICE, health professionals should involve patients in decisions about their 
medicines by making sure they communicate with them effectively. This includes adopting a 
style that gives the patient the opportunity to become involved in the conversation, asking 
open-ended questions to uncover their concerns, and encouraging the patient too to ask 
questions. Specifically, the health professional should include a conversation about what the 
patient hopes a new treatment will achieve, their views and concerns about the medication, 
and a discussion about the condition and how the medication will influence this, including the 
pros and cons. They should accept that the patient ultimately has the right to decide not to 
take the medication. Health professionals should also be aware that the patients might want to 
discuss a range of issues such as what happens if they are non-adherent, how they might 
reduce or stop longstanding medication, and how to make a choice between which of 
different medications to take. In due course, health professionals should assess the patient’s 
adherence to their medication by asking, in a non-judgemental way, about their medication 
taking, for example whether in the past week they have missed any doses. If the patient is not 
adhering to their medication, health professionals should tailor any intervention they offer to 
the specific difficulties the patient is experiencing as well as their preferences. If side-effects 
are a particular problem for the patient, then health professionals should allow the patient to 
make an informed choice about how to deal with these by discussing the benefits as well as 
the side-effects of the medication. The dose taken may need to be adjusted, the medication 
switched to another drug, or a different strategy might be needed, such as changing the timing 
of when the medication is taken.  
NICE published another relevant guideline, on medicines optimisation, in 2015 (NICE 
Medicines and Prescribing Centre, 2015). Also in line with a client-centred approach, 
medicines optimisation is defined as ‘a person-centred approach to safe and effective 
medicines use, to ensure people obtain the best possible outcomes from their medicines.’ This 
guideline recommends carrying out medication reviews, as well as using self-management 
plans and patient decision aids during medicines-related consultations. Similar to the NICE 
guidelines on medicines adherence, healthcare professionals completing medication reviews 
as part of medicines optimisation are asked to take into account the patient’s (and family 
members’ or carers’, where appropriate) views and understanding about their medicines as 
well as concerns, questions or problems they have with their medicines. Both of the NICE 
guidelines cited here are directed at health professionals who have competent knowledge and 
expertise about prescribing and medicines, such as doctors, nurses and pharmacists. But these 
health professionals often lack the psychological knowhow that underpins behaviour-change 
practices. One reasonable proposal to address this gap would be for closer, multi-disciplinary 
working that brings together the medicinal knowhow of pharmacists with the psychological 
expertise of practitioner psychologists to better support patients with their medication needs.  
How do these guidelines help us respond to the 60-year old female whose case I outlined at 
the start of this article? There are a number of issues to consider. It is clear that the patient is 
experiencing side-effects that she considers to be detrimental to her quality of life. In 
addition, she has been unable to discuss her concerns with her GP, whom she considers has 
no interest in her cancer treatment. These concerns are likely to lead the patient to become 
‘non-persistent’ with her medication, discontinuing the course of treatment early without first 
exploring her concerns with a health practitioner. The initial action then is to have a client-
centred discussion with the patient in order to further explore her beliefs about the 
medication, its benefits and also the extent of concerns she has with the side-effects. A 
practitioner psychologist would need to communicate with the other professionals involved in 
this patient’s care, for example the GP, in order to explain the patient’s beliefs, concerns and 
preferences, and suggest a medication review. During a medication review the patient may 
agree for her medication to be switched to another hormonal treatment or she may decide 
with the GP to stop taking the medication altogether. The key is the concordant approach that 
allows that open discussion and a joint decision about the medication to be reached with the 
patient.   
I posed a question earlier about progress made in relation to understanding and tackling 
medication non-adherence. Arguably, the goal of treatment should be to empower patients to 
self-manage their chronic illness. In this sense, current advice focusses on recognising 
individual differences and providing a concordant, client-centred solution rather than a one-
size-fits-all approach. But the problem of medication non-adherence remains a huge societal 
burden and much progress remains to be made in the field. Future research, for example, 
could examine the specific detail of a successful client-centred approach using methodology 
such as conversation analysis. The rapid advent of technology-enabled adherence services too 
provides considerable opportunity for ongoing research in the field. Currently, the best 
opportunity for providing adherence-focussed conversations, however, is at the point of 
prescribing and dispensing medication. Therefore, there is strong justification for asking the 
British Psychological Society and the different medical, pharmacy and nursing professional 
representative bodies to work together to improve the psychological knowhow of the wider 
group of professionals in the field including the prescribing and pharmacy workforce.  
 
- Parastou Donyai is an Associate Professor at the University of Reading  
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